- Home
- ESGL vs VTYX Comparison
ESGL vs VTYX Comparison
Compare ESGL & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESGL
- VTYX
- Stock Information
- Founded
- ESGL 1999
- VTYX 2018
- Country
- ESGL Singapore
- VTYX United States
- Employees
- ESGL N/A
- VTYX N/A
- Industry
- ESGL
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- ESGL
- VTYX Health Care
- Exchange
- ESGL Nasdaq
- VTYX Nasdaq
- Market Cap
- ESGL 154.3M
- VTYX 154.9M
- IPO Year
- ESGL N/A
- VTYX 2021
- Fundamental
- Price
- ESGL $3.60
- VTYX $2.33
- Analyst Decision
- ESGL
- VTYX Buy
- Analyst Count
- ESGL 0
- VTYX 2
- Target Price
- ESGL N/A
- VTYX $9.00
- AVG Volume (30 Days)
- ESGL 22.8K
- VTYX 434.1K
- Earning Date
- ESGL 09-23-2025
- VTYX 11-06-2025
- Dividend Yield
- ESGL N/A
- VTYX N/A
- EPS Growth
- ESGL N/A
- VTYX N/A
- EPS
- ESGL N/A
- VTYX N/A
- Revenue
- ESGL $6,099,784.00
- VTYX N/A
- Revenue This Year
- ESGL N/A
- VTYX N/A
- Revenue Next Year
- ESGL N/A
- VTYX N/A
- P/E Ratio
- ESGL N/A
- VTYX N/A
- Revenue Growth
- ESGL N/A
- VTYX N/A
- 52 Week Low
- ESGL $0.90
- VTYX $0.78
- 52 Week High
- ESGL $3.87
- VTYX $3.39
- Technical
- Relative Strength Index (RSI)
- ESGL 66.59
- VTYX 49.81
- Support Level
- ESGL $3.40
- VTYX N/A
- Resistance Level
- ESGL $3.73
- VTYX $2.54
- Average True Range (ATR)
- ESGL 0.26
- VTYX 0.14
- MACD
- ESGL 0.06
- VTYX -0.10
- Stochastic Oscillator
- ESGL 84.62
- VTYX 87.17
About ESGL ESGL Holdings Limited
ESGL Holdings Ltd is a waste management, treatment, and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical, and electroplating companies.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.